现在让我们来看一下不含anti-PD-(L)1单臂的双抗与anti-PD-(L)1组合的情况。如果说anti-PD-(L)1单抗的作用是“松开刹车”的主要方式,那桥接CD3和肿瘤关联抗原(TAA)的双抗就是“打火”,而桥接CD28和另一TAA的双抗则是“踩油门”的一种方式。anti-PD-(L)1单抗可以与“打火”双抗或“踩油门”双抗联用...
1、肿瘤侵润T细胞高的患者 (n=15),达到47%有效率和73%的疾病控制率 2、PD-L1表达超过1%患者 (n=15) ,达到44%有效率和69%的疾病控制率 国内临床进展 据君实首席运行官冯辉博士介绍,JS001在Clinicaltrials.gov一共注册有十项临床试验,针对15种不同癌症类型累计治疗超过200个患者。2016年完成三项I期临床试验的...
Cancer Treatment Reviews Volume 109, September 2022, 102428Clinical trial data of Anti–PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review Author links open overlay panelDouglas R. Adkins a, Robert I. Haddad bShow more Add to Mendeley Share Cite...
作者: BMS登记了一项三期临床试验NCT06561386,Anti-PD-1抗体Nivolumab(O药)+Anti-LAG-3抗体Relatlimab,在PD-L1表达量为1-49%的非鳞状晚期非小细胞肺癌的一线治疗中,默沙东Anti-PD-1抗体Pembrolizumab(K药)联合化疗的,头对头比对三期临床试验, 引用: 2024-08-21 15:46 看到在clinical trials网站上,BMS登记了一项...
在《anti-PD-(L)1联合用药策略》上两集里,介绍了肿瘤免疫周期和三类肿瘤,并聚焦肿瘤免疫周期的前三个阶段—察觉,渗入和破境。在本集里,我们将讨论肿瘤免疫周期的最后阶段:歼灭。 连环画 | 超级抗体 连环画 | 双特异性抗体 连环画 | Anti-PD-(L)1...
Our study suggests that the combination of a PD-1 antibody, an HDACi, and a VEGF antibody could be a promising treatment regimen for patients with MSS/pMMR advanced colorectal cancer. ClinicalTrials.gov registration: NCT04724239.This is a preview of subscription content, access via your ...
Thus, this meta-analysis evaluated the efficacy and safety of anti-PD-1/PD-L1 antibody therapy for pretreated patients with advanced NSCLC. Randomized clinical trials were retrieved by searching the PubMed, EMBASE, ASCO meeting abstract, clinicaltrial.gov, and Cochrane library databases. The pool...
Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: a meta-analysis of randomized clinical trials. Medicine (Baltimore) 2016; 95: e4611.Zhou GW, Xiong Y, Chen S, Xia F, Li Q and Hu J: Anti-PD- 1/PD-L1 antibody therapy for pretreated advanced non...
To compare the efficacy and toxicity of anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) versus docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Phase III randomised clinical trials (RCTs) were identified af...
The expression of PD1 and PD-L1 has drawn interest as potential therapeutic targets in oncology. Successful preclinical models of PD1/PD-L1 inhibition across a myriad of solid tumors resulted in an avalanche of clinical trials, which derived in decisive improvements of clinical outcomes in patients...